T2 Biosystems Announces 2017 Second Quarter Financial and Operational Results Release and Conference Call Date
July 20 2017 - 8:00AM
T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the
development of innovative diagnostic products to improve patient
health, today announced that it will release its 2017 second
quarter financial and operational results after the market closes
on Thursday, August 3, 2017. In conjunction with the release, the
Company will host a conference call with the investment community
at 4:30 p.m. Eastern Time on Thursday, August 3, 2017, to discuss
the financial results and other business developments.
Interested parties may access the live call via telephone by
dialing 1-877-407-9208 (U.S.) or 1-201-493-6784 (International). To
listen to the live call via T2 Biosystems' website, go to
www.t2biosystems.com, in the Investors/Events
& Presentations section. A webcast replay of the call will be
available following the conclusion of the call, also in the
Investors/Events & Presentations section of the website.
About T2 Biosystems T2 Biosystems is dedicated
to developing innovative diagnostic products to improve patient
health. With the FDA-cleared T2Dx® Instrument and T2Candida® Panel
targeting sepsis and a range of additional products in development,
T2 Biosystems is an emerging leader in the field of in vitro
diagnostics. The Company is utilizing its proprietary T2 Magnetic
Resonance technology, or T2MR®, to develop a broad set of
applications aimed at lowering mortality rates, improving patient
outcomes and reducing the cost of healthcare by helping medical
professionals make targeted treatment decisions earlier. T2MR
enables the fast and sensitive detection of pathogens, biomarkers
and other abnormalities in a variety of patient sample types,
including whole blood. For more information, please visit
www.t2biosystems.com.
Company Contact:
Darlene Deptula-Hicks, T2 Biosystems
SVP & Chief Financial Officer
ddeptula@t2biosystems.com
603-553-5803
Media Contact:
Matthew McKillip, T2 Biosystems
mmckillip@t2biosystems.com
518-577-3466
Investor Contact:
Chris Brinzey, Westwicke Partners
chris.brinzey@westwicke.com
339-970-2843
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024